The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients
Increasing evidence suggests that dysregulated immune responses are associated with the clinical outcome of coronavirus disease 2019 (COVID-19). Nucleocapsid protein (NP)-, spike (S)-, receptor binding domain (RBD)- specific immunoglobulin (Ig) isotypes, IgG subclasses and neutralizing antibody (NAb...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.632814/full |
| _version_ | 1818676562363416576 |
|---|---|
| author | Huanle Luo Huanle Luo Tingting Jia Jiamin Chen Shike Zeng Zengzhao Qiu Shu Wu Xu Li Yuxuan Lei Xin Wang Weihua Wu Renli Zhang Xuan Zou Tiejian Feng Ruxia Ding Yue Zhang Yao-Qing Chen Yao-Qing Chen Caijun Sun Caijun Sun Tian Wang Tian Wang Tian Wang Shisong Fang Yuelong Shu Yuelong Shu |
| author_facet | Huanle Luo Huanle Luo Tingting Jia Jiamin Chen Shike Zeng Zengzhao Qiu Shu Wu Xu Li Yuxuan Lei Xin Wang Weihua Wu Renli Zhang Xuan Zou Tiejian Feng Ruxia Ding Yue Zhang Yao-Qing Chen Yao-Qing Chen Caijun Sun Caijun Sun Tian Wang Tian Wang Tian Wang Shisong Fang Yuelong Shu Yuelong Shu |
| author_sort | Huanle Luo |
| collection | DOAJ |
| description | Increasing evidence suggests that dysregulated immune responses are associated with the clinical outcome of coronavirus disease 2019 (COVID-19). Nucleocapsid protein (NP)-, spike (S)-, receptor binding domain (RBD)- specific immunoglobulin (Ig) isotypes, IgG subclasses and neutralizing antibody (NAb) were analyzed in 123 serum from 63 hospitalized patients with severe, moderate, mild or asymptomatic COVID-19. Mild to modest correlations were found between disease severity and antigen specific IgG subclasses in serum, of which IgG1 and IgG3 were negatively associated with viral load in nasopharyngeal swab. Multiple cytokines were significantly related with antigen-specific Ig isotypes and IgG subclasses, and IL-1β was positively correlated with most antibodies. Furthermore, the old patients (≥ 60 years old) had higher levels of chemokines, increased NAb activities and SARS-CoV-2 specific IgG1, and IgG3 responses and compromised T cell responses compared to the young patients (≤ 18 years old), which are related with more severe cases. Higher IgG1 and IgG3 were found in COVID-19 patients with comorbidities while biological sex had no effect on IgG subclasses. Overall, we have identified diseases severity was related to higher antibodies, of which IgG subclasses had weakly negative correlation with viral load, and cytokines were significantly associated with antibody response. Further, advancing age and comorbidities had obvious effect on IgG1 and IgG3. |
| first_indexed | 2024-12-17T08:45:27Z |
| format | Article |
| id | doaj.art-a03a937b9f1e44fe821be434341c5202 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-17T08:45:27Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a03a937b9f1e44fe821be434341c52022022-12-21T21:56:13ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-03-011210.3389/fimmu.2021.632814632814The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 PatientsHuanle Luo0Huanle Luo1Tingting Jia2Jiamin Chen3Shike Zeng4Zengzhao Qiu5Shu Wu6Xu Li7Yuxuan Lei8Xin Wang9Weihua Wu10Renli Zhang11Xuan Zou12Tiejian Feng13Ruxia Ding14Yue Zhang15Yao-Qing Chen16Yao-Qing Chen17Caijun Sun18Caijun Sun19Tian Wang20Tian Wang21Tian Wang22Shisong Fang23Yuelong Shu24Yuelong Shu25School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaKey Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, Guangzhou, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaShenzhen Center for Disease Control and Prevention, Shenzhen, ChinaShenzhen Center for Disease Control and Prevention, Shenzhen, ChinaShenzhen Center for Disease Control and Prevention, Shenzhen, ChinaShenzhen Center for Disease Control and Prevention, Shenzhen, ChinaShenzhen Center for Disease Control and Prevention, Shenzhen, ChinaDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, ChinaDivision of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaKey Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, Guangzhou, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaKey Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, Guangzhou, ChinaDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United StatesDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, United StatesInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, United StatesShenzhen Center for Disease Control and Prevention, Shenzhen, ChinaSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, ChinaKey Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, Guangzhou, ChinaIncreasing evidence suggests that dysregulated immune responses are associated with the clinical outcome of coronavirus disease 2019 (COVID-19). Nucleocapsid protein (NP)-, spike (S)-, receptor binding domain (RBD)- specific immunoglobulin (Ig) isotypes, IgG subclasses and neutralizing antibody (NAb) were analyzed in 123 serum from 63 hospitalized patients with severe, moderate, mild or asymptomatic COVID-19. Mild to modest correlations were found between disease severity and antigen specific IgG subclasses in serum, of which IgG1 and IgG3 were negatively associated with viral load in nasopharyngeal swab. Multiple cytokines were significantly related with antigen-specific Ig isotypes and IgG subclasses, and IL-1β was positively correlated with most antibodies. Furthermore, the old patients (≥ 60 years old) had higher levels of chemokines, increased NAb activities and SARS-CoV-2 specific IgG1, and IgG3 responses and compromised T cell responses compared to the young patients (≤ 18 years old), which are related with more severe cases. Higher IgG1 and IgG3 were found in COVID-19 patients with comorbidities while biological sex had no effect on IgG subclasses. Overall, we have identified diseases severity was related to higher antibodies, of which IgG subclasses had weakly negative correlation with viral load, and cytokines were significantly associated with antibody response. Further, advancing age and comorbidities had obvious effect on IgG1 and IgG3.https://www.frontiersin.org/articles/10.3389/fimmu.2021.632814/fullSARS-CoV-2COVID-19host immune responseantibody responsecytokine productiondisease severity |
| spellingShingle | Huanle Luo Huanle Luo Tingting Jia Jiamin Chen Shike Zeng Zengzhao Qiu Shu Wu Xu Li Yuxuan Lei Xin Wang Weihua Wu Renli Zhang Xuan Zou Tiejian Feng Ruxia Ding Yue Zhang Yao-Qing Chen Yao-Qing Chen Caijun Sun Caijun Sun Tian Wang Tian Wang Tian Wang Shisong Fang Yuelong Shu Yuelong Shu The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients Frontiers in Immunology SARS-CoV-2 COVID-19 host immune response antibody response cytokine production disease severity |
| title | The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients |
| title_full | The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients |
| title_fullStr | The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients |
| title_full_unstemmed | The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients |
| title_short | The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients |
| title_sort | characterization of disease severity associated igg subclasses response in covid 19 patients |
| topic | SARS-CoV-2 COVID-19 host immune response antibody response cytokine production disease severity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.632814/full |
| work_keys_str_mv | AT huanleluo thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT huanleluo thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tingtingjia thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT jiaminchen thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT shikezeng thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT zengzhaoqiu thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT shuwu thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT xuli thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuxuanlei thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT xinwang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT weihuawu thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT renlizhang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT xuanzou thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tiejianfeng thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT ruxiading thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuezhang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yaoqingchen thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yaoqingchen thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT caijunsun thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT caijunsun thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tianwang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tianwang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tianwang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT shisongfang thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuelongshu thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuelongshu thecharacterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT huanleluo characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT huanleluo characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tingtingjia characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT jiaminchen characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT shikezeng characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT zengzhaoqiu characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT shuwu characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT xuli characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuxuanlei characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT xinwang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT weihuawu characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT renlizhang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT xuanzou characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tiejianfeng characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT ruxiading characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuezhang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yaoqingchen characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yaoqingchen characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT caijunsun characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT caijunsun characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tianwang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tianwang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT tianwang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT shisongfang characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuelongshu characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients AT yuelongshu characterizationofdiseaseseverityassociatediggsubclassesresponseincovid19patients |